Recent Advances in the Management of Adverse Events Associated with Lorlatinib

As a novel third-generation ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown excellent systemic and intracranial activity in non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations and progress on first- and second-generation TKIs. In comparison with other...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Dehua, Zhang, Jiwen, Yan, Ting, Chen, Shanshan, Li, Wei, Shangguan, Dangang, She, Zhihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492578/
https://www.ncbi.nlm.nih.gov/pubmed/37694103
http://dx.doi.org/10.2147/OTT.S426989
_version_ 1785104286584143872
author Liao, Dehua
Zhang, Jiwen
Yan, Ting
Chen, Shanshan
Li, Wei
Shangguan, Dangang
She, Zhihua
author_facet Liao, Dehua
Zhang, Jiwen
Yan, Ting
Chen, Shanshan
Li, Wei
Shangguan, Dangang
She, Zhihua
author_sort Liao, Dehua
collection PubMed
description As a novel third-generation ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown excellent systemic and intracranial activity in non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations and progress on first- and second-generation TKIs. In comparison with other ALK-TKIs, lorlatinib has a unique safety profile for hyperlipidemia and central nervous system adverse events. Lorlatinib-induced adverse events are well tolerated, permanent discontinuations are rarely reported, and dose modifications and/or standard medical therapy are useful for the management of adverse events. Our present study reviews the safety profile of lorlatinib as well as the relevant management strategies. Our present study aims to provide a practical guide for the scientific management and application of lorlatinib.
format Online
Article
Text
id pubmed-10492578
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104925782023-09-10 Recent Advances in the Management of Adverse Events Associated with Lorlatinib Liao, Dehua Zhang, Jiwen Yan, Ting Chen, Shanshan Li, Wei Shangguan, Dangang She, Zhihua Onco Targets Ther Review As a novel third-generation ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown excellent systemic and intracranial activity in non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations and progress on first- and second-generation TKIs. In comparison with other ALK-TKIs, lorlatinib has a unique safety profile for hyperlipidemia and central nervous system adverse events. Lorlatinib-induced adverse events are well tolerated, permanent discontinuations are rarely reported, and dose modifications and/or standard medical therapy are useful for the management of adverse events. Our present study reviews the safety profile of lorlatinib as well as the relevant management strategies. Our present study aims to provide a practical guide for the scientific management and application of lorlatinib. Dove 2023-09-05 /pmc/articles/PMC10492578/ /pubmed/37694103 http://dx.doi.org/10.2147/OTT.S426989 Text en © 2023 Liao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Liao, Dehua
Zhang, Jiwen
Yan, Ting
Chen, Shanshan
Li, Wei
Shangguan, Dangang
She, Zhihua
Recent Advances in the Management of Adverse Events Associated with Lorlatinib
title Recent Advances in the Management of Adverse Events Associated with Lorlatinib
title_full Recent Advances in the Management of Adverse Events Associated with Lorlatinib
title_fullStr Recent Advances in the Management of Adverse Events Associated with Lorlatinib
title_full_unstemmed Recent Advances in the Management of Adverse Events Associated with Lorlatinib
title_short Recent Advances in the Management of Adverse Events Associated with Lorlatinib
title_sort recent advances in the management of adverse events associated with lorlatinib
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492578/
https://www.ncbi.nlm.nih.gov/pubmed/37694103
http://dx.doi.org/10.2147/OTT.S426989
work_keys_str_mv AT liaodehua recentadvancesinthemanagementofadverseeventsassociatedwithlorlatinib
AT zhangjiwen recentadvancesinthemanagementofadverseeventsassociatedwithlorlatinib
AT yanting recentadvancesinthemanagementofadverseeventsassociatedwithlorlatinib
AT chenshanshan recentadvancesinthemanagementofadverseeventsassociatedwithlorlatinib
AT liwei recentadvancesinthemanagementofadverseeventsassociatedwithlorlatinib
AT shangguandangang recentadvancesinthemanagementofadverseeventsassociatedwithlorlatinib
AT shezhihua recentadvancesinthemanagementofadverseeventsassociatedwithlorlatinib

Ejemplares similares